The current status and prospects of theranostic in targeted radionuclide therapy

DING Ying; YANG Hui

doi:10.19732/j.cnki.2096-6210.2024.05.002

您当前的位置：

首页 >

文章列表页 >

The current status and prospects of theranostic in targeted radionuclide therapy

更新时间：2025-12-15

- The current status and prospects of theranostic in targeted radionuclide therapy
- Vol. 33, Issue 5, Pages: 470-474(2024)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6210.2024.05.002
  CLC：
- Published Online：07 November 2024，
  
  Published：07 November 2024
- 稿件说明：
移动端阅览
丁颖,杨辉. 诊疗一体化在物理靶向核素治疗中的应用现状及展望[J]. 肿瘤影像学, 2024, 33(5): 470-474 https://doi.

org/10.19732/j.cnki.2096-6210.2024.05.002
丁颖,杨辉. 诊疗一体化在物理靶向核素治疗中的应用现状及展望[J]. 肿瘤影像学, 2024, 33(5): 470-474 https://doi. DOI： 10.19732/j.cnki.2096-6210.2024.05.002.

org/10.19732/j.cnki.2096-6210.2024.05.002 DOI：

摘要

靶向放射性核素治疗（targeted radionuclide therapy，TRT）指通过各种手段使放射性药物在肿瘤组织内聚集的治疗方式。基于治疗方式的不同，TRT可分为化学/生物靶向内照射治疗与物理靶向内照射治疗。TRT一般指全身给药的化学/生物靶向核素治疗。随着核医学诊断治疗技术的不断发展和精准医学的推进，临床上已将分子影像与物理靶向核素治疗相结合，形成诊疗一体化的物理靶向核素治疗。本文以目前临床常见和新兴的物理靶向核素治疗为例，介绍诊疗一体化在物理靶向核素治疗中的应用现状及发展趋势。

Abstract

Targeted radionuclide therapy (TRT) leveraging the unique properties of radioactive pharmaceuticals to concentrate therapeutic effects within tumor tissues. TRT can be principally categorized into two distinct approaches based on the differences in targeting mechanisms: chemical/biological targeting internal radiotherapy and physical targeting internal radiotherapy. Generally

TRT refers to the systemic administration of targeted radionuclide drugs. The continuous advancement of nuclear medicine diagnostic and therapeutic technologies

coupled with the advocacy of precision medicine

has led to an innovative integration in clinical practice: integrated physical targeted radionuclide theranostics. This article explored the current status and development of theranostics in physically targeted radionuclide treatment

highlighting some common and emerging therapies in clinical practice.

关键词

Keywords

references

Views

365

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research advances in EphA2-targeted theranostic radiopharmaceuticals

⁶⁴Cu/¹⁷⁷Lu-DOTA-diZD, a small-molecule-based theranostic pair for triple-negative breast cancer

FAPI in radionuclide theranostics: toward a new emerging paradigm for tumor management

The value of ⁶⁸Ga-FAP-2286 PET/CT in predicting the survival of patients with advanced digestive system malignant tumors after treatment

Related Author

Xinyu LIU

Xiaoping XU

Shaoli SONG

Yuqian HUANG

Wei FAN

Ying DING

Hui YANG

PEI Wenjie

Related Institution

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Center for Biomedical Imaging, Fudan University

Shanghai Engineering Research Center of Molecular Imaging Probes

Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University

Department of Nuclear Medicine, Sun Yat-sen University Cancer Centre

AI问答

⁰